"Why i am not infected with HIV": Implications for long-term HIV risk reduction and HIV vaccine trials

Journal of Acquired Immune Deficiency Syndromes

Volumn 16, Issue 5, 1997, Pages 393-399

  Des Jarlais, Don C ^a,d   Vanichseni, Suphak ^b   Marmor, Michael ^a   Buavirat, Aumphornphun ^b   Titus, Steven ^a   Raktham, Suwanee ^b   Friedmann, Patricia ^a   Kitayaporn, Dwip ^b,c   Wolfe, Hannah ^a   Friedman, Samuel R ^a   Mastro, Timothy D ^b  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

^c HIV/AIDS Collaboration   (Thailand)

^d BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

AIDS; HIV; Injecting drug users; New york; Risk behavior; Substance abuse; Thailand; Vaccine

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ARTICLE; ATTITUDE; BEHAVIOR; CLINICAL TRIAL; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG USE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; INJECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK; SUBSTANCE ABUSE; THAILAND; UNITED STATES; VIRUS TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AMERICAS; ASIA; BEHAVIOR; BELIEFS; CULTURE; DEMOGRAPHIC FACTORS; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; DISEASES; DRUG USAGE; HIV INFECTIONS; IV DRUG USERS; NEW YORK; NORTH AMERICA; NORTHERN AMERICA; POPULATION; POPULATION CHARACTERISTICS; RESEARCH REPORT; RISK BEHAVIOR; RISK REDUCTION BEHAVIOR; SOUTHEASTERN ASIA; THAILAND; UNITED STATES; URBAN POPULATION; VIRAL DISEASES;

ADULT; AIDS VACCINES; COHORT STUDIES; CROSS-SECTIONAL STUDIES; HIV INFECTIONS; HIV SERONEGATIVITY; HUMANS; RISK-TAKING; SUBSTANCE ABUSE, INTRAVENOUS;

HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

EID: 0031445124     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199712150-00013     Document Type: Article

References (28)

1. Coates TJ, Aggleton P, Gutzwiller F, et al. HIV prevention in developed countries. Lancet 1996;348:1143-8.
2. Mann JM, Tarantola DJM, eds. AIDS in the world: II. New York: Oxford University Press, 1996.
3. Des Jarlais DC, Hagan HH, Friedman SR, et al. Maintaining low HIV seroprevalence in populations of injecting drug users. JAMA 1995;274:1226-31.
4. Stall R, Ekstrand ML, Pollack L, McKusick L, Coates TJ. Relapse from safer sex: the next challenge for AIDS prevention efforts. J Acquir Immune Defic Syndr 1990;3:1181-7.
5. Des Jarlais DC, Abdul-Quader A, Tross S. The next problem: maintenance of AIDS risk reduction among intravenous drug users. Int J Addict 1991;26:1279-92.
6. Holmberg S. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health 1996;86:642-54.
7. Friedman SR, Jose B, Deren S, Des Jarlais DC, Neaigus A. Risk factors for HIV seroconversion among out-of-treatment drug injectors in high and low seroprevalence cities. Am J Epldemiol 1995:142:864-74.
8. Des Jarlais DC, Choopanya K, Frischer M, Lima E, Friedmann P, Friedman SR. Cross-cultural similarities in AIDS risk reduction among injecting drug users. IX International Conference on AIDS, Berlin, 1993.
9. Des Jarlais DC, Choopanya K, Wenston J, et al. Risk reduction and stabilization of HIV seroprevalence among drug injectors in New York City and Bangkok, Thailand. In: Rossi GB, Beth-Giraldo E, Chieco-Bianchi L, Dianzani F, Giraldo G, Verani P, eds. Science challenging AIDS. Basel: S. Karger, 1992:207-13.
10. New York City Department of Health. AIDS surveillance update, fourth quarter, 1994. New York: New York City Department of Health, 1995.
11. New York City Department of Health. Report of the expert panel on HIV seroprevalence estimates and AIDS case projection methodologies. New York: New York City Department of Health, 1989.
12. Eisenhandler J, Drucker E. Opiate dependency among the subscribers of a New York area private insurance plan. JAMA 1993;269:2890-1.
13. Dvision of Epidemiology, Ministry of Public Health, Thailand. Summary of AIDS situation, weekly epidemiological surveillance report. Bangkok: Ministry of Public Health, 1996.
14. Mastro TD, Kitayaporn D, Weniger BG, et al. Estimating the number of HIV-infected injection drug users in Bangkok: a capture-recapture method. Am J Public Health 1994;84:1094-9.
15. Marmor M, Titus S, Wolfe H, et al. Retention, behavior change, and HIV-seroconversion among injecting drug users (IDUs) and sexual partners of IDUs. AIDS Res Hum Retroviruses 1994;10(Suppl. 2):S207-13.
16. Vanichseni S, Kitayaporn D, Mastro TD, et al. HIV-1 incidence and follow up in a prospective cohort of injecting drug users (IDUs) in Bangkok, Thailand. XI International Conference on AIDS. Vancouver, July, 1996.
17. Martin E. Toward an anthropology of immunology: the body as nation state. Med Anthropol Q 1990;4:410-26.
18. Bandura A. Social learning theory. Englewood Cliffs, NJ: Prentice-Hall, 1977.
19. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996;273:1856-62.
20. Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nature Med 1996;2:1240-3.
21. Paxton WA, Martin SR, Tse D, et al. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposures. Nature Med 1996;2:412-7.
22. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86:367-77.
23. Harrison C, Marmor M, Titus S, Cord-Cruz E, Des Jarlais D. Belief clusters among HIV-seroconverting drug users: implications for counseling. XI International Conference on AIDS. Vancouver, July, 1996.
24. Mastro T, deVincenzi I. Probabilities of HIV-1 transmission. AIDS 1996;10(Suppl.):S75-82.
25. Robertson N. Getting better: inside Alcoholics Anonymous. New York: Fawcett Crest, 1988.
26. Normand J, Vlahov D, Moses LE, eds. Preventing HIV transmission: the role of sterile needles and bleach. Washington, D.C.: National Academy Press/National Research Council/Institute of Medicine, 1995.
27. Lurie P, Bishaw M, Chesney MA, et al. Ethical, behavioral, and social aspects of HIV vaccine trials in developing countries. JAMA 1994;271:295-301.
28. Esparza J, Heyward W, Osmanov S. HIV vaccine development: from basic research to human trials. AIDS 1996;10:1-10.